Novel Embozene® Microspheres Discovered to Treat Symptomatic Knee Osteoarthritis

Varian discovered novel Embozene® microspheres to treat genicular artery embolization (GAE) for the patients with Knee Osteoarthritis.

The FDA cleared Embozene device is used for embolisation of hypervascular tumors, uterine fibroids, arteriovenous malformations and benign prostatic hyperplasia

Genicular Artery Embolization (GAE), is the novel minimally-invasive procedure which provides instant and long term pain relief for patients suffering with osteoarthritis (OA). It reduces the flow of blood to the periarticular tissue of the joints reducing the inflammatory process.

Genicular Artery Embolization (GAE) is supposed to be the new treatment option for clinicians which helps in reducing pain and economic burden of the disease.

Osteoarthritis is a common form of arthritis causing severe joint disease affecting the cartilage and surrounding tissues. In Osteoarthritis, knee is the most common affected area and most of the adult US population suffer with knee osteoarthritis.

Approximately 14 million US population have symptomatic knee osteoarthritis while half suffering from advanced knee osteoarthritis.

The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Embozene® Microspheres for Genicular Artery Embolization for Symptomatic Knee Osteoarthritis.